FOSTER CITY, Calif., July 1, 2022 /CSRwire/ - The U.S. Supreme Court delivered a decision in Dobbs v. Jackson Women’s Health Organization, which overturned the landmark 1973 Roe v. Wade ruling. This decision will have significant implications for women’s healthcare in roughly half of the states across the country – states where many of our colleagues, partner organizations and patients live and work. Improving health equity has always been core to our mission, including removing barriers faced by women, transgender individuals and other groups who are disproportionately impacted. This focus has always transcended our innovative medicines. As a healthcare organization, we understand medical decisions are deeply personal, and we believe they should be made by individuals with advice from their physicians.

As a company, our goal is to ensure  our employees and their dependents have access to the medical services they need, when they need them. We have ensured our medical plan covers reimbursement of travel and lodging expenses to cover employees who need to travel out of state in the U.S. to receive medical care related to women’s reproductive health services.

In addition, the Gilead Foundation will donate $1.5 million in support of organizations focused on reproductive health services. We have also initiated a special matching donation program where the Gilead Foundation will double any contributions made by individual employees up to the limit of $15,000.

Originally published by Gilead Sciences

Gilead Sciences

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

More from Gilead Sciences